Interaction of Endokinin A/B and (Mpa6)-Γ2-msh-6–12 in Pain Regulation in Mice

Lanxia Zhou,Qing Yang,Chunbo He,Chunnan Wei,Yinliang Yang,Shouliang Dong
DOI: https://doi.org/10.1016/j.npep.2015.06.007
IF: 3.152
2015-01-01
Neuropeptides
Abstract:The present study focused on the interactive effects of (Mpa6)-γ2-MSH-6–12 (Mpa, spinal level) and endokinin A/B (EKA/B, supraspinal level) on pain regulation in mice. EKA/B (30pmol) only weakened 100pmol Mpa-induced hyperalgesia at 5min, but could enhance it during 20–30min. However, EKA/B (100pmol) antagonized all dose levels of Mpa significantly at 5min and blocked them completely at 10min. EKA/B (3nmol) co-injected with Mpa presented marked analgesia at 5min and enduring hyperalgesia within 20–60min. To investigate the underlying mechanisms between Mpa and EKA/B, SR140333B and SR142801 (NK1 and NK3 receptor antagonists, respectively) were utilized. SR140333B had no influence on Mpa, while SR142801 potentiated it during 20–30min. Whereas, SR140333B and SR142801 could block the co-administration of Mpa and EKA/B (30pmol) separately at 5min and 30min. These phenomena might attribute to that these two antagonists promoted the antagonism of EKA/B (30pmol) at the early stage, while antagonized EKA/B preferentially in the latter period. SR140333B weakened the analgesia of EKA/B (3nmol), but produced no effect on Mpa. However, SR140333B failed to affect the co-injection of Mpa and EKA/B, which implied that EKA/B cooperated with Mpa prior to SR140333B. These results could potentially help to better understand the interaction of NK and MrgC receptors in pain regulation in mice.
What problem does this paper attempt to address?